Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks. Read why ACAD stock is a buy.

Among adults with obstructive sleep apnea, a combination of pimavanserin and atomoxetine taken for 1 week “greatly” lowered ...

Neurorehabilitation: Transforming lives via interdisciplinary approach for atypical Parkinsonism: Dr. Vignesh Srinivasan & Dr. Poovarasan Wednesday, August 6, 2025, 08:00 Hrs [IST ...

The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino ...